Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBT Margin (2023 - 2025)

Mangoceuticals' EBT Margin history spans 3 years, with the latest figure at 2934.9% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 108345.0% to 2934.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 4526.86%, a 311306.0% decrease, with the full-year FY2025 number at 4526.86%, down 311306.0% from a year prior.
  • EBT Margin hit 2934.9% in Q4 2025 for Mangoceuticals, up from 9043.49% in the prior quarter.
  • Over the last five years, EBT Margin for MGRX hit a ceiling of 733.99% in Q3 2023 and a floor of 9043.49% in Q3 2025.
  • Historically, EBT Margin has averaged 2624.53% across 3 years, with a median of 1734.3% in 2023.
  • Biggest five-year swings in EBT Margin: surged 143666bps in 2024 and later plummeted -754411bps in 2025.
  • Tracing MGRX's EBT Margin over 3 years: stood at 1050.87% in 2023, then tumbled by -76bps to 1851.45% in 2024, then tumbled by -59bps to 2934.9% in 2025.
  • Business Quant data shows EBT Margin for MGRX at 2934.9% in Q4 2025, 9043.49% in Q3 2025, and 3221.61% in Q2 2025.